Tuberous Sclerosis Complex (TSC) - Market Outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Tuberous Sclerosis Complex (TSC)

Tuberous Sclerosis Complex (TSC), Thelansis Epidemiology study reflects there is 1 in 6,000 newborns in the United States. Approximately 40,000 to 80,000 people in the United States have tuberous sclerosis. The prevalence in Europe is estimated to be approximately 1 in 25,000 to 1 in 11,300. As many as 2 million people worldwide are believed to have the disorder.

Competitive landscape of TSC includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of TSC across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

TSC Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing , Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Tuberous sclerosis complex (TSC) Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. N.        Asset        Company        Stage

1        Drug: RAD001        Novartis Pharmaceuticals        Phase 3

2        Drug: Sirolimus 0.2%        Aucta Pharmaceuticals, Inc        Phase 2

3        Drug: NPC-12G gel        Nobelpharma        Phase 3

4        Drug: Ganaxolone        Marinus Pharmaceuticals        Phase 2

5        Drug: Aspirin        Shijiazhuang Yiling Pharmaceutical Co. Ltd        Phase 2

6        Drug: Rapamune        Pfizer        Phase 1

7        Drug: Vatiquinone        PTC Therapeutics        Phase 3

8        Drug: TAK-935        Takeda        Phase 2

9        Drug: Circadin 2/5/10 mg        Neurim Pharmaceuticals Ltd.        Phase 3

10        Drug: TAK-935        Ovid Therapeutics Inc.        Phase 2

Diffuse intrinsic pontine gliomas (DIPG) - Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Diffuse Intrinsic Pontine Gliomas (DIPG)

Epidemiology study suggests Incidence is 1 to 2 cases per 100,000 population. DIPG has a peak incidence of 6-9 years and a slight preference for males. Among all the tumors in children, they represent 20% of them.

KOLs insights DIPG across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Competitive landscape of diffuse intrinsic pontine gliomas (DIPG) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Market Forecasting - Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing , Market Event and Product Event , Country specific Forecast Model , Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario , Summary and Insights.

Read more: Diffuse intrinsic pontine gliomas (DIPG) Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 S.N.        Asset        Company        Stage

1        Drug: BXQ-350        Bexion Pharmaceuticals, Inc.        Phase 1

2        Drug: PTC596        PTC Therapeutics        Phase 1

3        Drug: Temozolomide        Genentech, Inc.        Phase 1

4        Drug: ONC201        Chimerix        Phase 1

5        Drug: Panobinostat Nanoparticle Formulation MTX110        Midatech Pharma US Inc.        Phase 2

6        Drug: DSP-7888        Sumitomo Dainippon Pharma Co., Ltd.        Phase 2

7        Biological: Ad-RTS-hIL-12        Ziopharm        Phase 2

8        Drug: Crenolanib        Arog Pharmaceuticals, Inc.        Phase 1

9        Biological: DNX-2401        DNAtrix, Inc.        Phase 1

10        Biological: DNX-2401        Alcyone Lifesciences, Inc.        Phase 1

11        Drug: GDC-0084        Kazia Therapeutics Limited        Phase 1

12        Drug: REGN2810        Regeneron Pharmaceuticals        Phase 2

13        Drug: Marizomib        Celgene        Phase 1

14        Drug: Mebendazole        Janssen Pharmaceuticals        Phase 2

15        Drug: ribociclib        Novartis        Phase 1

16        Drug: Indoximod        NewLink Genetics Corporation        Phase 1

17        Drug: Indoximod        Lumos Pharma        Phase 1

18        Drug: Palbociclib        Pfizer        Phase 1

19        Drug: 9-ING-41        Actuate Therapeutics Inc.        Phase 1

20        Biological: Nivolumab        Bristol-Myers Squibb        Phase 2

21        Biological: NKTR-214        Nektar Therapeutics        Phase 2

22        Drug: Depatuxizumab mafodotin        AbbVie        Phase 2

23        Drug: Abemaciclib        Eli Lilly and Company        Phase 1

24        Drug: CLR 131        Cellectar Biosciences, Inc.        Phase 1

Osteosarcoma Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 Indication name: Osteosarcoma

Osteosarcoma Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Osteosarcoma is not a common cancer. Each year, about 1,000 new cases of osteosarcoma are diagnosed in the United States.

Competitive landscape of Osteosarcom includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing , Market Event and Product Event , Country specific Forecast Model , Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario , Summary and Insights.

KOL insights across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Read more: Osteosarcoma Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

1.  Drug: ALMB-0168        AlaMab Therapeutics (Shanghai) Inc.        Phase 2

2. Drug: Lenvatinib        Merck Sharp & Dohme Corp.        Phase 2

3. Drug: ZN-c3        K-Group Beta        Phase 2

4. Drug: ZKAB001 5mg/kg        Lee's Pharmaceutical Limited        Phase 2

5. Drug: Calcium Folinate        Isofol Medical AB        Phase 2

6. Drug: Lenvatinib        Eisai Limited        Phase 2

7. Drug: Cisplatin liposomal        Insmed Incorporated        Phase 2

8. Drug: Inhaled Lipid Cisplatin (ILC)        Eleison Pharmaceuticals LLC.        Phase 2

9. Drug: Nivolumab        Bristol-Myers Squibb        Phase 2

10.Drug: Apatinib        Jiangsu HengRui Medicine Co., Ltd.        Phase 2

11. Drug: Sirolimus combined with CP, MT and ZA        Reliable Cancer Therapies        Phase 1

12.  Drug: Sirolimus combined with CP, MT and ZA        Pfizer        Phase 1

13. Drug: Olaparib        AstraZeneca        Phase 2

14. Drug: M6620        EMD Serono        Phase 2

15. Drug: IBI188        Innovent Biologics (Suzhou) Co. Ltd.        Phase 1

16. Drug: GM-CSF        Y-mAbs Therapeutics        Phase 2

17. Drug: CLR 131        Cellectar Biosciences, Inc.        Phase 1

18. Drug: Pazopanib Hydrochloride        GlaxoSmithKline        Phase 2

19. Device: ExAblate 2100        InSightec        Phase 2

20. Biological: Aldesleukin        Iovance Biotherapeutics, Inc.        Phase 2

21. Drug: compound 31543 Calcitriol        Berg, LLC        Phase 1

22. Combination Product: MASCT-I,PD1 Antibody, Apatinib        SYZ Cell Therapy Co..        Phase 1

23. Biological: CRX100 suspension for infusion        Bio Eclipse Therapeutics        Phase 1

24. Drug: cisplatin        Novartis        Phase 3

25. Drug: cisplatin        Chugai Pharmaceutical        Phase 3

26. Drug: Enoblituzumab Macro Genics        Phase 1

27. Biological: CAB-AXL-ADC Bio Atla, Inc.        Phase 2

28. Drug: KCP-330        Karyopharm Therapeutics Inc        Phase 1

29.  Drug: BAY806946        Bayer        Phase 2

30. Drug: 177Lu-3BP-227 (also called 177Lu-IPN01087)        Ipsen        Phase 2

31. Drug: 9-ING-41        Actuate Therapeutics Inc.        Phase 2

32. Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)        Jennerex Biotherapeutics        Phase 1

33. Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)        Silla Jen, Inc.        Phase 1

34. Biological: Nivolumab        Nektar Therapeutics        Phase 2

35. Drug: plerixafor        Genzyme, a Sanofi Company        Phase 2

36. Drug: Seclidemstat        Salarius Pharmaceuticals, LLC        Phase 1

37. Biological: Vigil        Gradalis, Inc.        Phase 2

38. Drug: Talazoparib        Medivation, Inc.        Phase 1

39. Drug: Eribulin mesilate        Eisai Inc.        Phase 2

40. Biological: Vigil        Gradalis, Inc.        Phase 3

41. Drug: TK216        Oncternal Therapeutics, Inc        Phase 1

42. Drug: VAL-413 Valent Technologies, Inc. Phase 1

43. Drug: AMG 479 Nant Cell, Inc. Phase 2

44. Drug: Lipegfilgrastim Teva Pharmaceutical Industries Phase 1

45. Biological: IMC-A12 (cixutumumab) Eli Lilly and Company Phase 2

46.  Drug: Gemcitabine Celgene Corporation Phase 1

47. Drug: Durvalumab MedImmune LLC Phase 2

48. Drug: Cyclophosphamide, Topotecan, and Bevacizumab  Genentech, Inc. Phase 2"

Alport Syndrome – Market Outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Report Summary:

Thelansis “Alport Syndrome (AS) - Market outlook, Epidemiology, Market Forecast and Competitive Landscape - 2018 To 2030 ”  this report provides a comprehensive study of the disease area landscape and changing market dynamics with  respect to the current & future market events for the 8 MM countries (USA, EU5, Japan & China).

The report provides a comprehensive view of disease events, classification, severity level, stages, identified and emerging biomarkers, progression, manifestations, symptoms, risk factors, pathogenesis, genetic basis and treatment guidelines at country level.

Disease overview:

Alport syndrome is an inherited progressive form of glomerular disease that is often associated with sensorineural hearing loss and ocular defects. The primary abnormality arises from mutations in genes encoding the type IV collagen protein family. This syndrome is a genetically heterogeneous disease having different mutations and forms of inheritance: X-linked (mutations in COL4A5 gene), autosomal recessive (homozygous or compound heterozygous mutations in COL4A3 or COL4A4 genes) and autosomal dominant.

Epidemiology:

The total number of Alport syndrome increased from 128,924 in 2018 to 182,305 by 2030. The USA comprises of ~38 of the total diagnosed cases of AS followed by China, EU5 and Japan. ~80% cases had typical glomerular basement membrane (GBM) changes of AS, ~10% patients initially had pathology features of diffuse thinning of the GBM only, 14% patients showed pathology of focal segmental glomerulosclerosis (FSGS).

Read more: Alport Syndrome – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Market Scenario:

Current clinical practice recommendations for delaying end stage renal disease in patients with Alport syndrome focus on early introduction of RAAS inhibitors to suppress urinary protein excretion.

KOL insights: KOLs across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Competitive Landscape:

Considering Alport syndrome is an excellent model of CKD with proteinuria and fibrosis, orphan drug designation with premium pricing benefits, number of patients to be treated will be substantial and finally s no approved treatment several drug candidates are in Phase II and II/ III stages of development by various companies.

Market Forecasting: Thelansis’ research team expects the Alport syndrome market potential for 2030 at $X.XXB in 8MM countries. Out of this market, 68.5% sales are expected to be contributed from the US market whereas XX.X% is expected to come from EU-5. Japan and China are expected to contribute XX.X% and X.X% respectively.

* Alport syndrome current market stands at $XXXX.XM which is expected to grow from 2019 to 2024 at a CAGR of X.X%. Majorly this is expected because of expected approvals of pharmacotherapies in the space.

Contact Us:

About Thelansis: As the name depicts Thelansis is specialized in “Therapy Area Landscape Analysis” along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products. Our Syndicated primary market research reports include Market Insight, Pipeline Insight, Product Insight, Specialized Reports, Indication Outlook and Market Access Reports. Ask for our report offerings, and Indication specific sample pages by sharing your email ID with us at, p.potdar@thelansis.com.

Peeyush Potdar

Delivery Head:

Email: p.potdar@thelansis.com

Visit us at http://www.thelansis.com/

Delivery office

B-1030, C Wing

Vrindavan tech village Marathahalli

Outer ring road, Bangalore- 560037

Sales office

183-Asylum Street Hartfort, CT-06103, USA

Telephone

USA +1-302-380-3552, India +91-9899921259

Email

clientsupport@thelansis.com, sales@thelansis.com

Cushing’s Syndrome (CS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Report Overview:

Cushing’s syndrome is a disorder that occurs when your body makes too much of the hormone cortisol over a long period of time.

The report provides a comprehensive view of disease events, types, severity level, identified and emerging biomarkers, progression, manifestations, symptoms, risk factors, pathogenesis, genetic basis and treatment guidelines at country level.

Etiology:

Cushing’s syndrome can be caused by overuse of cortisol medication, as seen in the treatment of chronic asthma or rheumatoid arthritis (iatrogenic Cushing’s syndrome), excess production of cortisol from a tumor in the adrenal gland or elsewhere in the body (ectopic Cushing’s syndrome) or a tumor of the pituitary gland secreting adrenocorticotropic hormone (ACTH) which stimulates the over-production of cortisol from the adrenal gland (Cushing’s disease).

Epidemiology:

An estimated 10-15 per million people are affected every year.

Geography Covered

* North America- United States and Canada

* EU5- Germany, France, Italy, Spain, and the United Kingdom

* Other EU Countries- Sweden, Denmark, Austria, Finland, Belgium, Netherlands, Switzerland, Poland, Russia

* Japan

* APAC- Singapore, China, India, New Zealand, Australia

* LATAM- Brazil, Mexico, Argentina

* Middle East (Israel, Saudi Arabia and the United Arab Emirates, Morocco, Egypt, Turkey, Algeria).

 

Read more: Cushing’s Syndrome (CS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Current Clinical Practice and Treatment Algorithm

Country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs are being covered under this section of the study. Retrospective analysis and bench-marking of clinical study outcomes are being presented in terms of Pr-treatment & post-treatment clinical and demographic patient characteristics.

KOL Insights - KOLs across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Competitive Landscape:

Competitive landscape includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review such as Orphan drug designation, Fast track, Priority review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation and Accelerated Approval are being tracked and supplemented with analyst commentary.

Clinical Trial Assessment:

Detailed clinical trial data analysis and key product positioning includes trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events.

Market Forecasting - Thelansis’ research team expects the Cushing’s syndrome market potential for 2030 at $X.XXB in 8MM countries. Out of this market, 68.5% sales are expected to be contributed from the US market whereas XX.X% is expected to come from EU-5. Japan and China are expected to contribute XX.X% and X.X% respectively.

Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country specific Forecast Model

- Market uptake and patient share uptake

Unmet Medical Needs Overview:

This report presents the most important clinical unmet needs in the treatment, according to Thelansis’s primary market research and analysis. Other important unmet needs identified through our research, include decreased cost burden on patients, improved administration convenience, and improved patient compliance. Our Syndicated research reports include Market Insight, Pipeline Insight, Product Insight, Specialized Reports, Indication Outlook and Market Access Reports.

Thelansis is specialized in Therapy Area Landscape Analysis along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products.

Acromegaly – Market outlook, Epidemiology, Market Fore- cast and Competitive Landscape Report – 2020 To 2030

Disease overview (Classification of Acromegaly)

• Ø  Approved and Emerging therapies (Pipeline assessment and key clinical trials profile)
• Ø  Epidemiology (Incidence, prevalence, mortality and survival)
• Ø  Market share and patient share uptake
• Ø  KOL’s perspective on current treatment & unmet needs
• Ø  Market and product event analysis
• Ø  Market forecast 2020 - 2030 (11 years of future market projections)

Report Summary

Thelansis “Acromegaly - Market outlook, Epidemiology, Market Forecast and Competitive Land- scape - 2020 To 2030 ”  this report provides a comprehensive study of the disease area land- scape and changing market dynamics with  respect to the cur- rent & future market events for the 8 MM countries (USA, EU5, Japan & China).

Report Overview

The report provides a comprehensive view of disease events, classification, identified and emerging, Clinical Manifestations, progression, signs & symptoms, risk factors, pathogenesis, genetic basis and treatment guidelines at country level

View Report: Acromegaly – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Acromegaly Market Comprehensive insight on patient segmentation based on Origin (Pituitary Tumor & Non-Pituitary Tumor), Adenoma size (Macroadenomas and Microadenomas), responsive to treatment (Surgical & Non-surgical), Clinical Manifestations (osteoarticular manifestation, cardiovascular manifestation, respiratory manifestation, gastrointestinal manifestation, endocrinological and other manifestations) has been provided into the epidemiology (Incidence and Prevalence) section of the  Acromegaly and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China

Drug utilization and analysis on the current clinical practice, KOL perspective on upcoming therapies, estimated TPP for pipeline as- sets, clinical characteristics upcoming therapies and future treatment paradigm.

Market aggregation on newly diagnosed patient pool, Thelansis estimation on persistence, compliance, adherence and a historic view of changing market dynamics and product-level patient flow of Acromegaly in the 8 MM Countries for the period 2020 – 2030.

Forecast Model – Snapshot

Epidemiology

Disease Overview

 

Acromegaly is a hormonal disorder that results from the availability of too much growth hormone (GH) in the body. The pituitary, a small gland in the brain, makes GH. In acromegaly, the pituitary produces excessive amounts of GH. Usually, the excess GH comes from benign, or noncancerous, tumors on the pituitary. These benign tumors are called Adenomas.

 

Competitive Landscape

 

Acromegaly Market Scenario:

 

There are three dimension treatment pattern are being under practice such as; surgery, medical therapy and radiotherapy. Pituitary surgery is recommended as the primary treatment in patients with microadenomas and in patients with macroadenomas that are associated with local mass effects or are enclosed and potentially curable surgically because surgery can lead to durable control of the tumor mass and associated biochemical effects.

 

Acromegaly Market Forecast

Thelansis’ research team expects the Acromegaly market potential for 2030 at $X.XXB in 8MM countries. Out of this market, 52.5% sales are expected to be contributed from the US market whereas XX.X% is expected to come from EU-5. Japan and China are expected to contribute XX.X% and X.X% respectively.

Acromegaly Products Pricing Scenario:

Upcoming therapy probably transform the treatment paradigm of Acromegaly in the near future. Clinical trials some level of promising results like proportion of patients maintaining their baseline and in most of the patients, without causing significant safety concerns. Of course, some questions about targeted therapy still remain un- solved.

Based on the KOL Insights gathered from Primary Market Research (PMR) of Acromegaly market Thelansis expects upcoming therapies may raise significant concerns with respect to the treatment cost as much as USD 85,000 to USD 124,000 per patient. To control the cost research have developed algorithm for tiered testing guide to enhance the clinical diagnosis of Acromegaly, in the other hand it is hard to distinguish genetic variations such as pin- pointing the phenotype and exact biomarker.

Contact Us

About Thelansis: - As the name depicts Thelansis is specialized in “Therapy Area Landscape Analy- sis” along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products. Our Syndicated research reports include Market Insight, Pipeline Insight, Product Insight, Specialized Reports, Indication Outlook and Market Access Reports. Our focused therapeutic approach provides our clients with clinical and disease area expertise from an integrated team of academic, medical, and industry specialists of our panel, Ask for our report offerings, and Indication specific sample pages by sharing your email ID with us at,

p.potdar@thelansis.com

Peeyush Potdar

Delivery Head:

Email: p.potdar@thelansis.com

Visit us at http://www.thelansis.com/

Delivery office

B-1030, C Wing

Vrindavan tech village Marathahalli

Outer ring road, Bangalore- 560037

Sales office

183-Asylum Street Hartfort, CT-06103, USA

Telephone

USA +1-302-380-3552 India +91-9899921259

Email

clientsupport@thelansis.com sales@thelansis.com